MAFLD, patient-centred care, and APASL.
APASL
Clinical trials
MAFLD
Patient-centred care
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
25
07
2022
accepted:
12
08
2022
pubmed:
8
9
2022
medline:
5
10
2022
entrez:
7
9
2022
Statut:
ppublish
Résumé
Asian-Pacific nations are home to more than half the world's population and similar to other global super regions, metabolic dysfunction associated fatty liver disease (MAFLD) is the principal cause for chronic liver disease. To address the challenges ahead for tackling the disease at-scale, the Asian Pacific Association for the Study of the Liver (APASL) was the first pan-national society to endorse and lead the process for redefining the disease and adopting the more appropriate term "MAFLD" with its accompanying set of positive diagnostic criteria. As with this initiative, APASL and Hepatology International will continue to strive to lead the field and work with sister societies towards full adoption of MAFLD. This will advance the science and practice of Hepatology and help incorporate MAFLD within multidisciplinary care teams. Ultimately, it will lead to more cogent clinical trials built on innovative design platforms that include patients with any disease related to metabolic dysfunction. For our patients, an outcome of these endeavours will be the provision of holistic person-centred care for this disease that is so common in our region.
Identifiants
pubmed: 36070122
doi: 10.1007/s12072-022-10408-6
pii: 10.1007/s12072-022-10408-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1034Informations de copyright
© 2022. Asian Pacific Association for the Study of the Liver.
Références
Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia–Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5:167–228
doi: 10.1016/S2468-1253(19)30342-5
Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573–e582
doi: 10.1016/j.cgh.2021.02.030
Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919
doi: 10.1007/s12072-020-10094-2
Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, et al. Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700
doi: 10.1210/clinem/dgac321
Eslam M, George J. Genetic insights for drug development in NAFLD. Trends Pharmacol Sci. 2019;40:506–516
doi: 10.1016/j.tips.2019.05.002
Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6:73–79
doi: 10.1016/S2468-1253(20)30294-6
Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 (e1991)
doi: 10.1053/j.gastro.2019.11.312
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209
doi: 10.1016/j.jhep.2020.03.039
Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864–873
doi: 10.1016/S2468-1253(21)00183-7
Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int. 2017;37:1389–1396
doi: 10.1111/liv.13397
Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6:57–64
doi: 10.1016/S2468-1253(20)30213-2
Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65–72
doi: 10.1016/S2468-1253(20)30340-X
Spearman CW, Desalegn H, Ocama P, Awuku YA, Ojo O, Elsahhar M, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J Hepatol. 2021;74:1256–1258
doi: 10.1016/j.jhep.2021.01.015
Méndez-Sánchez N, Maris-Gil S, Alonso-Rivera CG. Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease. J Hepatol. 2022;77:249
doi: 10.1016/j.jhep.2021.12.020
Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454–461
doi: 10.1016/j.jhep.2021.05.003
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388–390
doi: 10.1016/S2468-1253(22)00062-0
Eslam M, Ahmed A, Després J-P, Jha V, Halford JC, Chieh JTW, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743–753
doi: 10.1016/S2468-1253(21)00132-1
Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251–260
doi: 10.1097/MOG.0000000000000823
Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018–3030
doi: 10.1111/liv.14675
Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51:1115–1128
doi: 10.1111/hepr.13685
Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol. 2021;74:1254–1256
doi: 10.1016/j.jhep.2020.12.035
Alem SA, Gaber Y, Abdalla M, Said E, Fouad Y. Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol. 2021;74:1261–1262
doi: 10.1016/j.jhep.2021.01.022
Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia–Pacific region. Clin Mol Hepatol. 2022;28:150
doi: 10.3350/cmh.2021.0310